MARLIN, Romain; DESJARDINS, Delphine; CONTRERAS, Vanessa; LINGAS, Guillaume; SOLAS, Caroline; ROQUES, Pierre; NANINCK, Thibaut; PASCAL, Quentin; BEHILLIL, Sylvie; MAISONNASSE, Pauline; LEMAITRE, Julien; KAHLAOUI, Nidhal; DELACHE, Benoit; PIZZORNO, Andres; NOUGAIREDE, Antoine; LUDOT, Camille; TERRIER, Olivier; DEREUDDRE-BOSQUET, Nathalie; RELOUZAT, Francis; CHAPON, Catherine; HO TSONG FANG, Raphael; VAN DER WERF, Sylvie; ROSA CALATRAVA, Manuel; MALVY, Denis; DE LAMBALLERIE, Xavier; GUEDJ, Jeremie; LE GRAND, Roger

doi:10.1038/s41467-022-32565-w

Langue

Article de revue

Ce document a été publié dans

Nature Communications. 2022-08-30, vol. 13, n° 1

Résumé en anglais

The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have been largely tested in clinical trials but failed so far to bring clear evidence of clinical efficacy is favipiravir, a nucleoside analogue with large spectrum activity against several RNA viruses in vitro and in small animal models. Here, we evaluate the antiviral activity of favipiravir against Zika or SARS-CoV-2 virus in cynomolgus macaques. In both models, high doses of favipiravir are initiated before infection and viral kinetics are evaluated during 7 to 15 days after infection. Favipiravir leads to a statistically significant reduction in plasma Zika viral load compared to untreated animals. However, favipiravir has no effects on SARS-CoV-2 viral kinetics, and 4 treated animals have to be euthanized due to rapid clinical deterioration, suggesting a potential role of favipiravir in disease worsening in SARS-CoV-2 infected animals. To summarize, favipiravir has an antiviral activity against Zika virus but not against SARS-CoV-2 infection in the cynomolgus macaque model. Our results support the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/170139

DOI

http://dx.doi.org/10.1038/s41467-022-32565-w

Projet Européen

A global alliance for Zika virus control and prevention
European Vaccine Research and Development Infrastructure

Project ANR

Infrastructure nationale pour la modélisation des maladies infectieuses humaines

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates